Literature DB >> 12362920

Single plasma concentrations of 1'-hydroxymidazolam or the ratio of 1'-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects.

Janyce F Rogers1, Anne N Nafziger, Angela D M Kashuba, Daniel S Streetman, Mario L Rocci, Edna F Choo, Grant R Wilkinson, Joseph S Bertino.   

Abstract

The 30-minute ratio of 1'-hydroxymidazolam:midazolam plasma concentrations has been used as a measure of midazolam clearance in liver transplant patients. This study determined if a single concentration of 1'-hydroxymidazolam or the ratio of 1'-hydroxymidazolam:midazolam could be used to predict midazolam clearance in healthy subjects. Plasma midazolam and 1'-hydroxymidazolam concentrations from three previous studies were used for analyses. Data obtained predose and at 5, 30, 60, 120, 240, 300, and 360 minutes following intravenous doses of midazolam in 61 adults were divided and used to derive and validate equations to predict midazolam clearance. Equations were derived using linear regression and then validated by comparing predicted to observed clearance. Only one equation was related to midazolam clearance as afunction of 1'-hydroxymidazolam, but it did not predict midazolam clearance (r = 0.29, p = 0.31). Single sampling of 1'-hydroxymidazolam or 1'-hydroxymidazolam:midazolam plasma concentrations cannot be used to predict midazolam clearance in healthy adults.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12362920     DOI: 10.1177/009127002401382614

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  10 in total

1.  Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity.

Authors:  Chin B Eap; Thierry Buclin; Gianni Cucchia; Daniele Zullino; Elisabeth Hustert; Gabriela Bleiber; Kerry Powell Golay; Anne-Catherine Aubert; Pierre Baumann; Amalio Telenti; Reinhold Kerb
Journal:  Eur J Clin Pharmacol       Date:  2004-04-28       Impact factor: 2.953

2.  Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin.

Authors:  Bill Gurley; Martha A Hubbard; D Keith Williams; John Thaden; Yudong Tong; W Brooks Gentry; Philip Breen; Danielle J Carrier; Shreekar Cheboyina
Journal:  J Clin Pharmacol       Date:  2006-02       Impact factor: 3.126

3.  Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping.

Authors:  Bettina Link; Manuel Haschke; Nathalie Grignaschi; Michael Bodmer; Yvonne Zysset Aschmann; Markus Wenk; Stephan Krähenbühl
Journal:  Br J Clin Pharmacol       Date:  2008-04-11       Impact factor: 4.335

4.  Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.

Authors:  E D Kharasch; A Francis; A London; K Frey; T Kim; J Blood
Journal:  Clin Pharmacol Ther       Date:  2011-05-11       Impact factor: 6.875

5.  Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil.

Authors:  E D Kharasch; S Vangveravong; N Buck; A London; T Kim; J Blood; R H Mach
Journal:  Clin Pharmacol Ther       Date:  2011-02-23       Impact factor: 6.875

6.  Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam.

Authors:  Stephanie Katzenmaier; Christoph Markert; Gerd Mikus
Journal:  Eur J Clin Pharmacol       Date:  2010-08-03       Impact factor: 2.953

7.  Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants.

Authors:  Christine Y Malati; Sarah M Robertson; Jennifer D Hunt; Cheryl Chairez; Raul M Alfaro; Joseph A Kovacs; Scott R Penzak
Journal:  J Clin Pharmacol       Date:  2011-06-06       Impact factor: 3.126

8.  Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions.

Authors:  Scott R Penzak; Kristin H Busse; Sarah M Robertson; Elizabeth Formentini; Raul M Alfaro; Richard T Davey
Journal:  J Clin Pharmacol       Date:  2008-04-16       Impact factor: 3.126

Review 9.  Cytochrome P450 enzyme mediated herbal drug interactions (Part 1).

Authors:  Sompon Wanwimolruk; Virapong Prachayasittikul
Journal:  EXCLI J       Date:  2014-04-02       Impact factor: 4.068

10.  Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping.

Authors:  Joanna C Masters; Denise M Harano; Howard E Greenberg; Shirley M Tsunoda; In-Jin Jang; Joseph D Ma
Journal:  Ther Drug Monit       Date:  2015-02       Impact factor: 3.681

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.